Food allergy
A reproducible immune-mediated reaction to a specific food, ranging from immediate IgE-mediated urticaria or anaphylaxis to delayed non-IgE-mediated skin and gastrointestinal disease; it is distinct from non-immune food intolerance.
In a nutshell
Food allergy is a reproducible immune reaction to a specific food. Immediate IgE-mediated disease causes urticaria, angioedema, vomiting, wheeze or anaphylaxis; delayed non-IgE-mediated disease commonly causes eczema or gastrointestinal symptoms. Diagnose from an allergy-focused history, use focused IgE testing for suspected IgE-mediated disease and a supported elimination/reintroduction pathway for non-IgE disease. Confirmed allergy needs safe avoidance, dietetic support and a written emergency plan; do not describe withdrawn Palforzia guidance as a routine new-start option.
Classic presentation
A child develops reproducible lip swelling, urticaria and vomiting within minutes of eating a suspected food, often with eczema or another atopic condition.
Key points
- The history determines whether an immediate IgE-mediated, delayed non-IgE-mediated, mixed or non-immune process is most likely.
- A positive specific-IgE or skin-prick test indicates sensitisation and only supports allergy when it matches the clinical history.
- There are no validated routine tests for non-IgE-mediated food allergy; use a defined elimination and planned reintroduction pathway.
- Do not use serum IgG panels, Vega testing, kinesiology, hair analysis or other unvalidated tests to diagnose food allergy.
- Treat anaphylaxis immediately with IM adrenaline; do not delay for antihistamines, steroids or testing.
- Extensive avoidance can cause nutritional deficiency, faltering growth and anxiety; use dietetic support and reassess tolerance.
- NICE TA769 has been withdrawn: no new UK Palforzia starts should be described, although existing treatment may continue under the current transition arrangement.
First-line investigation
An allergy-focused history, followed by focused specific-IgE blood testing or skin-prick testing when immediate IgE-mediated allergy is suspected.
Management
Treat anaphylaxis without delay
Build the diagnosis from timing and phenotype
- Record the exact food, amount, timing, preparation, reproducibility, co-factors and symptoms by organ system; distinguish immediate IgE-mediated disease from delayed non-IgE disease, mixed patterns and food intolerance.1,2
- Use focused specific-IgE or skin-prick testing only when the history suggests IgE-mediated disease; interpret results with the clinical history and avoid broad panels.1,2
Make avoidance nutritionally safe
- Use a time-limited elimination and planned reintroduction for suspected non-IgE disease, with dietetic support for children, multiple-food exclusion, breast-feeding, formula changes, faltering growth or nutritional risk.1,2
- Provide label-reading, cross-contamination, school and childcare advice; maintain tolerated foods and treat asthma, eczema, rhinitis, reflux or constipation according to their own pathways.1,3,12,6
Refer and plan prevention
- Refer suspected anaphylaxis, severe or recurrent reactions, diagnostic uncertainty, significant nutritional restriction, faltering growth or need for oral challenge to specialist allergy care; provide two trained auto-injectors where risk warrants them.1,10,11
- Describe Palforzia accurately: NICE TA769 has been withdrawn and no new people should start it in the UK under the current information; existing patients may continue under the stated transition arrangements.14
Exam traps
- Food allergy is immune-mediated; food intolerance is not and does not cause IgE-mediated anaphylaxis.
- A positive allergy test alone does not diagnose clinical allergy.
- Do not order broad food-allergy panels or unvalidated IgG tests.
- Do not use a home oral challenge for suspected IgE-mediated allergy; specialist supervised challenge may be required.
- Do not continue a diagnostic elimination diet indefinitely without planned reintroduction and nutritional review.
- Do not call Palforzia a routine new-start UK option while NICE TA769 remains withdrawn.
Illustrations
Key sources
- NICE CG116: Food allergy in under 19s: assessment and diagnosis (NICE clinical guideline CG116; allergy-focused history, IgE-mediated and non-IgE-mediated diagnosis, elimination and reintroduction, referral, dietetic support and avoidance of unvalidated tests; published 23 February 2011 and last reviewed 21 September 2018.)Updated 23 Feb 2011
- BSACI: Food allergy investigations (BSACI clinical resource stating that history is essential, focused specific-IgE or skin-prick testing supports suspected IgE-mediated allergy, validated tests are lacking for non-IgE disease, and oral food challenge is the diagnostic gold standard; accessed August 2026.)Updated 13 Jan 2025
- NICE QS118: Food allergy in under 19s (NICE quality standard QS118 covering diagnosis, management, referral and support for food allergy in children and young people; published 24 March 2016.)Updated 24 Mar 2016
- NICE NG258: Anaphylaxis: assessment and referral after emergency treatment (NICE guideline NG258; current post-anaphylaxis documentation, observation, auto-injector and allergy-referral pathway; published 27 May 2026 and last reviewed 4 June 2026.)Updated 4 Jun 2026
- BSACI: Diagnosis and management of pollen food syndrome/oral allergy syndrome (BSACI guideline on the clinical history, focused testing and management of pollen-food syndrome, including the possibility of severe or atypical reactions; guideline published 2022.)Updated 1 Jan 2022
- NICE NG1: Gastro-oesophageal reflux disease in children and young people (NICE guideline relevant to reflux-like symptoms and alternative diagnoses in children with suspected food allergy; updated 2019.)Updated 9 Oct 2019
- NICE CG86: Recognition and assessment of coeliac disease (NICE guideline for considering and testing for coeliac disease when gastrointestinal symptoms mimic food allergy; updated 2017.)Updated 20 Sept 2017
- Resuscitation Council UK: Emergency treatment of anaphylactic reactions (RCUK healthcare-provider guideline for acute anaphylaxis treatment; most recent version published May 2021.)Updated 1 May 2021
- BNF online (Current UK prescribing information for adrenaline, antihistamines and related acute medicines; check the live entries, product information and local protocols before prescribing.)
- NICE NG258: Referral to a specialist allergy service (NICE NG258 recommendation to offer age-appropriate specialist allergy referral after emergency treatment for suspected anaphylaxis.)Updated 27 May 2026
- MHRA: Adrenaline Auto-Injectors safety campaign (MHRA guidance on early auto-injector use, carrying two devices, lying down, calling 999, training and expiry checks; published April 2023 and updated June 2023.)Updated 19 Jun 2023
- NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management (NICE asthma guideline used for coexisting asthma assessment and optimisation; updated 2021.)Updated 31 Mar 2021
- NICE NG198: Secondary bacterial infection of eczema and other common skin conditions (NICE antimicrobial prescribing guidance relevant to avoiding inappropriate antibiotic treatment for eczema flares; published 25 May 2021.)Updated 25 May 2021
- NICE TA769: Palforzia for treating peanut allergy in children and young people (Current NICE TA769 information states that the guidance has been withdrawn because the initial dose-escalation pack was discontinued; no new people should start Palforzia in the UK, while existing treatment may continue until March 2027 under the stated arrangements.)Updated 2 Feb 2022
This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.

